← Eichor
Study identifier: NCT05685173 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

Condition: B-cell Non-Hodgkins Lymphoma (B-NHL)  ·  Sponsor: Regeneron Pharmaceuticals

PhasePhase 1
Planned participants107
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug\[s\]"), in patients with relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (B-NHLs). The study has 2 parts. The aim of the first part (dose escalation) is to find a safe dose of REGN5837 when given in combination with odronextamab. The goal of the second part (dose expansion) is to use the REGN5837 drug dose found in the first part to see how well REGN5837 in combination with odronextamab works. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (that could make the drugs less effective or could lead to side effects)

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trials Administrator  ·  844-734-6643  ·  clinicaltrials@regeneron.com

Always discuss trial participation with your own doctor first.

Locations (20)

City of HopeDuarte, California, United StatesRecruiting
University of California Los Angeles (UCLA) Medical CenterSanta Monica, California, United StatesRecruiting
Norton Cancer InstituteLouisville, Kentucky, United StatesRecruiting
Massachusetts General HospitalBoston, Massachusetts, United StatesRecruiting
Harvard Medical School - Beth Israel Deaconess Medical CenterBoston, Massachusetts, United StatesRecruiting
Rutgers Cancer Institute of New JerseyNew Brunswick, New Jersey, United StatesRecruiting
NYU Langone Health Perlmutter Cancer CenterNew York, New York, United StatesRecruiting
Icahn School of Medicine at Mount SinaiNew York, New York, United StatesRecruiting
UT SouthwesternDallas, Texas, United StatesRecruiting
CHU de BordeauxTalence, New Aquitaine, FranceRecruiting
Hopital Saint LouisParis, FranceRecruiting
Gustave RoussyVillejuif, Île-de-France Region, FranceRecruiting

+ 8 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05685173